Icon

VIZAMYL (nda203137)- (40.5mCi/10ML (4.05mCi/ML),121.5mCi/30ML (4.05mCi/ML))

FLUTEMETAMOL F-18 GE HEALTHCARE
40.5mCi/10ML (4.05mCi/ML),121.5mCi/30ML (4.05mCi/ML)
No No
2028-Sep-16 2018-Oct-25
None None
None No
Vizamyl is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline.
0 0 0
Total Other Developers None
Drugs with Suitability No
40.5mCi/10ML (4.05mCi/ML) ** ** - - -
121.5mCi/30ML (4.05mCi/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.